Shots:
- ViiV Healthcare has reported 12mos. interim data from P-IIb (EMBRACE) trial assessing lotivibart (IV or SC, Q4M) + cabotegravir (CAB LA; IM, QM) vs SoC for the treatment of HIV
- lotivibart + cabotegravir maintained viral suppression in 94% of lotivibart IV & 82% of SC recipients vs 88%, with confirmed virologic failure in 4% (2/50), 6% (3/49) & 4% (1/26) from IV, SC & oral SoC groups, respectively
- Presented at CROI 2026, the data highlighted lotivibart’s ultra-long-acting potential and support continued study progression, incl. evaluation of a twice-yearly IV dosing regimen
Ref: GSK | Image: ViiV | Press Release
Related News: ViiV Healthcare Reports P-III (LATITUDE) Trial of Cabenuva in Adherence-Challenged HIV Patients
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
